1. Introduction {#s0005}
===============

The Democratic Republic of the Congo (DRC) has among the highest total fertility rates in the world (6.6 children) and a very low modern contraceptive prevalence rate (mCPR of 7.8% among women married or in union as of 2013--14) [@bb0005]. Recent research underscores numerous cultural, social and financial barriers to modern contraceptive use: fear of side effects (especially sterility), costs of the method, sociocultural norms (especially the dominant position of the male in family decision making), pressure from family members to avoid modern contraception and lack of information/misinformation [@bb0010].

Although societal norms reinforce large families, mCPR has increased in the past 5 years in the capital city of Kinshasa, from 18.5% in 2013 to 26.7% in 2017 [@bb0015]. As of 2017, injectable contraceptives represented 19.5% of modern method use among women in union [@bb0015]. In recent years, the DRC government has shown strong support for increasing mCPR [@bb0020], consistent with the National Multisectoral Plan for Family Planning: 2014--2020 [@bb0025]. This study tested an innovative strategy for increasing contraceptive access, which, if successful, could be scaled up to further contribute to the national effort of increasing mCPR.

DMPA-SC emerged in 2011 as a promising new option that could increase access to contraception, especially at the community level in low-income countries [@bb0030]. The product is a subcutaneous formulation of the intramuscular injectable contraceptive depot medroxyprogesterone acetate (DMPA-IM), available in the prefilled Uniject™ injection system [@bb0035]. Because it is effective, reversible and discrete, DMPA-SC has great potential to increase contraceptive use worldwide [@bb0040]. Further benefits include usability while breastfeeding, ease of administration and extremely low levels of unintended pregnancies [@bb0045]. Given its ease of administration, DMPA-SC lends itself to task-shifting to lower-level health care workers [@bb0035], [@bb0050] and to self-injection, which has yielded positive user experiences in seven countries where tested [@bb0045], [@bb0055], [@bb0060], [@bb0065] and increased continuation among users [@bb0070].

In the DRC, only physicians and nurses give injections. A 2015 pilot study in Kinshasa used medical and nursing (M/N) students to deliver DMPA-SC and other methods at the community level. It showed that women were highly satisfied with the method and service received from these providers [@bb0075], [@bb0080]. Local Ministry of Health (MOH) officials encouraged further testing of innovative strategies. The objectives of this study were to assess the feasibility of training M/N students to instruct women in the community to self-inject DMPA-SC; the willingness of clients to self-inject over receiving DMPA-SC from a provider; and user satisfaction with DMPA-SC as a method, self-injection as a procedure and counseling/instruction from the M/N students.

2. Materials and methods {#s0010}
========================

2.1. Intervention {#s0015}
-----------------

We carried out the study in three of the 35 health zones in Kinshasa: Kintambo (urban), Lingwala (urban) and Nsele (rural). The research team partnered with a local NGO, *Action en Santé et Dévéloppement* (ASD), which has extensive experience in family planning training, to oversee the implementation of the intervention. Specifically, ASD arranged for participation of one medical and five nursing schools, including supervisors and students from the 2015 pilot; obtained relevant health zone authorization; developed training curriculum for educating/coaching women to self-inject; and coordinated free family planning "campaign days" in the community with health zone personnel. The students received a vest with a family planning logo and knapsack containing contraceptives, supplies (foam cushion to practice self-injection, sterile gloves, lidocaine, alcohol) and data collection forms.

On campaign days previously announced to the community, 10--15 students arrived at a location adjacent to a health center and provided counseling and services (pills, condoms, CycleBeads or DMPA-SC) onsite to eligible clients. The students referred women to fixed facilities for methods requiring a trained family planning provider for initiation (e.g., IUD and implant). At baseline, women interested in DMPA-SC were encouraged to try self-injection, but they could instead choose the provider-administered injection.

Women opting for self-injection at baseline were invited to practice injection on a *mousse* (a thick piece of foam mimicking skin and approved as a mannequin by the DRC Ministry of Health); they then self-injected as the M/N student supervised. Students assessed competency to self-inject (on their own body) based on a checklist of 23 items that included Uniject preparation, skin disinfection, DMPA-SC injection and waste disposal, among others. Clients had to correctly perform 80% (\> 18) of these items to be declared competent by the M/N students.

2.2. Data collection {#s0020}
--------------------

Data collection for this research consisted of (a) surveys conducted by trained interviewers at baseline and follow-up at 3, 6 and 12 months among DMPA-SC clients; (b) a survey among the M/N students about their experience as providers; and (c) in-depth interviews with MOH and health zone personnel. This analysis is limited to the acceptor surveys (baseline and follow-ups). Interviewers entered data on Android smartphones that have been programmed with the Open Data Kit application; data were immediately transferred to a server, which the research team regularly monitored.

### 2.2.1. Baseline {#s0025}

#### 2.2.1.1. Initial acceptor survey (Nov. 2016--Jan. 2017) {#s0030}

The intervention and data collection took place simultaneously in the three different health zones. Female interviewers experienced in contraceptive surveys received refresher training on the questionnaire content and survey procedures; they were present on campaign days. After a woman accepted DMPA-SC --- either via self-injection or injected by the student --- she was invited to participate in the baseline study. Clients who accepted the interview then moved from the student to the interviewer, who obtained informed consent. We aimed to enroll all DMPA-SC acceptors. However, because some acceptors were unable to wait while interviewers completed other interviews, we reverted to a convenience sample of clients available for the interview after receiving DMPA-SC. At baseline, interviewers obtained contact information for all participants willing to participate in follow-up surveys.

On all rounds of data collection, the wording on questions regarding the client\'s experience included four categories that the interviewer read: "very \_\_\_," "somewhat\_\_\_," "not very \_\_\_\_" and "not at all" (anxious, satisfied, etc.).

#### 2.2.1.2. Three-month follow-up (Feb. 2017--May. 2017) {#s0035}

Community agents working for the health zone publicized a second round of campaign days, at which all DMPA-SC acceptors could receive a second dose. For clients who failed to return for the 3-month follow-up on campaign days, interviewers attempted to locate them in their homes or by phone. Because the research focused on DMPA-SC self-injection, only clients judged competent to self-inject by the 3-month follow-up were retained in the sample for the 6- and 12-month follow-up. At 3 months, these clients received three doses of DMPA-SC to cover home self-injection at 6, 9 and 12 months.

#### 2.2.1.3. Follow-up at 6 months (May--Jul. 2017) and 12 months (Nov, 2017--Jan. 2018) {#s0040}

After the first two rounds, there were no further campaign days. The research team located self-injectors (1) by phone, to establish a time and place for the interview, or (2) in their homes, via the community extension worker. [Fig. 1](#f0005){ref-type="fig"} presents the number of cases retained at each round and the reasons for attrition. Over different rounds, some questions were dropped and new ones added to track self-injectors\' experience over time.Fig. 1Participant flow diagram for the DMPA-SC self-injection study in Kinshasa, DRC.\*The sample size (*n*) on the previous round is used as the denominator for the subsequent round.Fig. 1

2.3. Analysis {#s0045}
-------------

The researchers used Stata (version 13) to complete a descriptive analysis of the data.

To assess a possible selection bias resulting from attrition, we treated each survey (baseline, 3-month, 6-month and 12-month) as independent from each other; then, we conducted bivariate analyses, *χ*^2^ statistics for categorical variables and analysis of variance (ANOVA) for continuous variables to compare the baseline sample to each follow-up sample on sociodemographic characteristics. We assessed statistical differences at an alpha level of .05.

Although this approach might not be best suited for longitudinal designs and could potentially lead to a lower likelihood to find significant differences, it was the best available approach given that we were unable to track participants as a unique longitudinal sample.

This research received human subjects approval from Tulane University (\#911338-7) and the Kinshasa School of Public Health (\#ESP-CE/071/2016). All the participants provided written consent before their inclusion in this research.

3. Results {#s0050}
==========

3.1. Willingness to self-inject among women selecting DMPA-SC on campaign days {#s0055}
------------------------------------------------------------------------------

On the first campaign days held for the purposes of this study, a total of 850 women chose DMPA-SC as their method. Of these, 640 women (75.3%) opted for self-injection over an injection by the M/N student. After being trained, the clients self-injected in front of the student. Women choosing not to self-inject cited fear of injecting incorrectly, fear of hurting themselves and greater trust in the provider (data not shown).

3.2. Sociodemographic characteristics of self-injectors at baseline and follow-up surveys {#s0060}
-----------------------------------------------------------------------------------------

At baseline, the 640 DMPA-SC self-injectors were 27 years old on average; only one in five had completed secondary school. Three quarters were married or in union; close to 100% had at least one child, with the average being three; two thirds wished to have more children, often after several years. Only half were employed (and of those, most were paid in kind, not cash) ([Table 1](#t0005){ref-type="table"}).Table 1Sociodemographic characteristics of women opting for DMPA-SC self-injection through a community-level program in Kinshasa, DRCTable 1Sociodemographic characteristicsBaseline\
(*n*=640)3-month follow-up\
(*n*=504)6-month follow-up\
(*n*=239)12-month follow-up\
(*n*=136)Age in years Mean26.727.428.5\*\*\*28.5\*\* (SD)(6.5)(6.8)(7.1)(6.9)Last year, education Primary or no education21.117.3\*14.615.4 Some level secondary56.964.159.856.6 Completed secondary or higher22.018.725.527.9Married or in union75.973.271.169.1Has living children99.198.499.698.5Number of children Mean3.13.23.4\*3.5\* (SD)(1.8)(1.9)(2.1)(1.8)Employed50.644.4\*44.447.1[^1]

This study was conducted in a community context, without the benefit of client records available through fixed health facilities. We experienced severe loss to follow-up between surveys. Due to logistical problems, the student providers and interviewers returned 1 week late for the designated 3-month follow-up/campaign days (potentially affecting an estimated 15% of DMPA-SC acceptors interviewed at baseline). Interviewers were present on the designated campaign days for the rest of the 3-month follow-up (and all subsequent data collection). They interviewed all baseline respondents (provider-injected or self-injected DMPA acceptors) who attended, as well as attempting to locate others by phone or home visit.

At 3-month follow-up, 131 cases (15.4%) were lost to follow-up. Among the 719 located, 504 (70.1%) self-injected at 3 months; 68 (9.5%) reported discontinuing DMPA-SC; eight (1.1%) had a pending injection; 130 (18.1%) were interviewed but dropped from the analysis because of the above-mentioned delay of resupply/interview at 3 months; and nine (1.3%) requested injection by the provider. At 6 months, an additional 129 (17.9% of 3-month sample) were lost to follow-up. Among the 375 clients located, 239 (63.7%) reported to have self-injected at 6 months, 40 (10.7%) had discontinued DMPA-SC, eight (2.1%) received the injection from someone else, and 88 (23.5%) still expected to self-inject. By 12 months, we located 204 clients; 136 (66.7%) reported to have self-injected at 12 months, whereas 24 (11.8%) had discontinued DMPA-SC, three (1.5%) received the injection from someone else, and 41 (20.1%) still expected to self-inject; see [Fig. 1](#f0005){ref-type="fig"}. In short, 75.3% of the 850 DMPA-SC clients at baseline opted for self-injection. The percentage of the original 850 whom we located, interviewed and determined to still be self-injecting was 59.3% (at 3 months), 28.1% (6 months) and 16.0% (12 months). These percentages should not be confused with continuation rates due to the large loss to follow-up. Over the course of the research, respondents in later rounds of the survey tended to be slightly better educated but less likely to be married or employed.

3.3. Contraceptive history among self-injectors at baseline (*n*=640) {#s0065}
---------------------------------------------------------------------

Less than half of the self-injectors (46.3%) had ever used a contraceptive method; 15.8% had ever used an injectable, and 2.2% had used DMPA-SC ([Table 2](#t0010){ref-type="table"}). Among previous injectable users, most (61.4%) used an appointment card to remember the date of the next injection, with far fewer mentioning a calendar, note to self or "just remembered." Despite these aids, 28.7% had missed an injection. Most previous injectable users (77.2%) had stopped using the injection because of desire to get pregnant, concern about (future) fertility, nonavailability of the method, side effects or a health problem. Among previous users of any method, half had used male condoms and withdrawal, followed by rhythm and the pill.Table 2Baseline contraceptive history of users of DMPA-SC self-injection in Kinshasa, DRCTable 2VariablesBaseline\
(*n*=640)Previous users of any contraceptive method46.3Previous users of an injectable15.8Previous users of DMPA-SC2.2Among previous users of an injectable:*n*=101 Strategies to remember reinjection date: Appointment card61.4 Calendar22.8 Note15.8 Memorization15.8 Other1.0 Ever missed an injection28.7 Stopped using an injectable77.2 Reasons for stopping an injectable: Wanted another pregnancy39.7 Concerns about fertility16.7 Nonavailability of method14.1 Side effects11.5 Other health problems11.5 Contraceptive use after stopping the injectable changed method:30.8 Stopped using contraception66.7 Can\'t remember2.6Among previous users of any method;*n*=195 Contraceptive methods ever used: Male condom54.4 Withdrawal52.3 Calendar43.6 Pill27.2 Other21.0 Most recent method used: Withdrawal28.7 Male condom23.1 Rhythm18.0 Pill16.4 Other13.9

For 61.7% of the self-injectors, DMPA-SC was their method of choice; almost all the remainder would have preferred an implant. Half (48.2%) came for services based on their own decision; for 37.8%, it was a joint decision with their husband or partner. Among those married or in union, about three quarters reported that their husband or partner was favorable to family planning. However, at least a quarter felt that some members of their community, including family and friends, opposed family planning (data not shown in tables).

3.4. Experiences of DMPA-SC self-injectors at baseline and follow-up at 3, 6 and 12 months {#s0070}
------------------------------------------------------------------------------------------

At baseline (*n*=640), most acceptors chose self-injection because it would be easy to perform at home (58.8%); one in five also mentioned liking to learn new things and to be able to manage this product themselves. Four in five considered themselves to be "very motivated" to try self-injection. Almost half (47.5%) reported being somewhat or very anxious at their first injection because of fear of the needle or pain. Close to 30% reported pain during the first injection, but less than 10% felt pain afterwards (data not shown.)

At baseline, 65.2% reported the first self-injection was somewhat or very easy (those finding it difficult mentioned problems of inserting the needle and pumping the medication). Most (90.3%) felt very well prepared by the training from the M/N students to perform self-injection. Over 90% felt confident to perform self-injection, to follow the instructions in the booklet on self-injection and to remember the date for their next injection ([Table 3](#t0015){ref-type="table"}). Most (67.5%) planned to rely on an appointment card (*jeton)* to remember the date of the next injection, with far fewer mentioning the calendar, a written note or "just remembering." Only 8.0% expressed that they would want to seek help from a family member or someone else for the next injection.Table 3Experience of the DMPA-SC self-injectors in Kinshasa, DRC, at baseline and at 3-, 6- and 12-month follow-up surveysTable 3VariablesBaseline[a](#tf0005){ref-type="table-fn"}\
(*n*=640)3-month follow-up\
(*n*=504)6-month follow-up\
(*n*=239)12-month follow-up\
(*n*=136)Level of anxiety about self-injection compared to previous round As anxious-5.610.011.8 Less anxious-86.984.980.2 More anxious-7.53.44.4 No answer-0.01.73.7Level of difficulty of performing self-injection Very difficult14.82.8\-- Somewhat difficult20.05.6\-- Somewhat easy24.722.6\-- Easy40.568.9\--Level of difficulty of the most recent self-injection compared to the previous round*n*=399 Less difficult-90.573.286.5 As difficult-9.023.912.0 More difficult-0.52.91.5Reason of difficulty about self-injection (multiple answers allowed):*n*=223*n*=43 Inserting the needle75.367.4-28.6 Express all the liquid27.420.9-25.0 Knowing where to inject14.8\-\-- Everything was easy11.7\-\-- Remembering the date\-\--14.3 Prepare DMPA-SC-27.9-17.9 Prepare skin-14.0\-- Waste disposal\-\--28.6 Other13.914.0\--Strategies to remember the date of next injection (multiple answers allowed): Appointment card/jeton67.5-68.254.4 Calendar12.7-5.07.4 Note11.3\-\-- Just remember7.2-27.644.1 Other1.4-9.28.8Positive aspects of using DMPA-SC in self-injection (multiple answers allowed): Effective to prevent pregnancies\--66.565.4 Easy to use\--45.261.0 Allows to control fertility decisions\--20.18.8 Less side effects\--13.47.4 Easy to hide\-\--16.9 Protects for a long time\-\--14.7 Other\--31.05.9Negative aspects of using SMPA-SC in self-injection: No negative aspects\--43.161.8 Side effects\--25.521.3 No answer\--19.77.4 Doses are hard to obtain\--5.46.6 Other\--7.11.5Level of confidence about how to perform self-injection of DMPA-SC: Very confident83.59\-\-- Confident12.34\-\-- Somewhat confident1.88\-\-- Not very confident0.0\-\-- Not confident2.19\-\--Level of confidence the self-injection of DMPA-SC was performed correctly: Very confident-89.1\-- Confident-0.0\-- Somewhat confident-9.1\-- Not very confident-0.8\-- Not confident-1.0\--Level of confidence about following the instructions in the booklet to self-inject DMPA-SC: Very confident80.16\-\-- Confident12.97\-\-- Somewhat confident0.78\-\-- Not confident2.34\-\-- Don\'t know3.75\-\--Level of confidence about when to perform to perform the injection: Very confident83.4494.4\-- Confident13.59\-\-- Somewhat confident0.784.2\-- Not confident1.880.5\-- Don\'t know0.310.8\--Willing to seek help from family member or friends for the next injection:8.0-0.01.5To whom will you ask for help? Community-based distributor70.59\-\-- Health care provider31.37\--75.0 Friend13.73\-\-- Other family member13.73\-\-- Other7.84\--25.0[^2]

At 3 months (*n*=504), the experience with self-injection was similar, though 86.9% mentioned feeling less anxious and 90.5% found it less difficult than at baseline. Nine in 10 (89.1%) felt very confident that they had self-injected correctly. Half (54.1%) reported side effects, the most common being irregular period, heavy and frequent bleeding, no period and abdominal pain. Some 20.4% had experienced skin reactions at the site of injection after self-injection, but among these women, only 1.9% had sought treatment for the reaction ([Table 4](#t0020){ref-type="table"}).Table 4Safety of DMPA-SC self-injection among users in Kinshasa, DRC, at 3-, 6- and 12-month follow-up surveysTable 4Variables3-month follow-up\
*n*=5046-month follow-up\
*n*=23912-month follow-up *n*=136Skin reactions after self-injection20.412.523.5Sought help for skin reaction1.90.03.1Ever experienced side effects while using DMPA-SC51.4-58.8Side effects ever experienced Heavy bleeding38.6-8.8 No period33.6-61.3 Irregular period31.3-28.8 Weight gain\--8.8 Other13.5-7.5Relative severity of side effects (percentage of users reporting \[side effect\] was tolerable or somewhat tolerable): Irregular periods\--95.7 No period\--83.7 Heavy bleeding\--85.7 Weight gain\--100.0Help seeking for the side effects: Irregular period\--30.4 No period\--22.5 Heavy bleeding\--71.4 Weight gain\--0.0Evolution of side effects (percentage of users reporting \[side effect\] had resolved by the time of the interview): Irregular period\--39.1 No period\--16.3 Heavy bleeding\--57.1 Weight gain\--14.3

Confidence remained high that they would remember the date of the next injection (98.7%) and that they would correctly perform it next time (99.5%).

At 6-month follow-up (*n*=239), respondents cited the effectiveness of DMPA-SC in preventing pregnancies (66.5%) and its ease of use (45.2%) as the most positive aspects of DMPA-SC self-injection. The negative aspects of self-injecting DMPA-SC included its side effects (25.5%) and unavailability of the method (5.4%); however, 43.1% reported no negative aspects of self-injecting DMPA-SC ([Table 3](#t0015){ref-type="table"}).

The findings from the 12-month follow-up (*n*=136) produced few new results compared to the 6-month follow-up; 13.5% still found self-injection "as or more difficult" as when they started, with inserting the needle and expressing the medication still the main reasons. By contrast, 61.8% reported no negative aspects to self-injection.

Almost all self-injectors at 3, 6 and 12 months expected to self-inject in the future. Reasons given (at 3-month follow-up) were their confidence that they could do self-injection and the convenience of not having to go to the health facility.

3.5. Reasons for discontinuation {#s0075}
--------------------------------

Given the large loss to follow-up between rounds of data collection, we have not presented data on discontinuation rates. However, of 76 self-injectors who discontinued between baseline and 3 months, the main reasons were the desire to stop the method (*n*=45), partner opposed (*n*=12) and change to another contraceptive method (*n*=11). At 6- and 12-month follow-up, discontinuers frequently cited fear of side effects (data not shown).

3.6. Management of doses of DMPA-SC at home (6-month follow-up; *n*=239) {#s0080}
------------------------------------------------------------------------

Clients judged competent to self-inject at 3 months were to receive three doses of DMPA-SC for subsequent reinjections at 6, 9 and 12 months at home. Most self-injectors (80.5%) reported that 3 months earlier, they had received at least one dose of DMPA-SC to take home (one dose: 2.9%, two doses: 22.2%, three doses: 76.0%). Almost all had a safe place to store it at home (e.g., in a closet, suitcase, handbag). Most disposed of the waste in trashcans (51.5%), latrines (42.3%) or "discarded outside" (11.6%) (data not shown.)

3.7. Satisfaction with the M/N students as educators in self-injection at baseline (*n*=640) {#s0085}
--------------------------------------------------------------------------------------------

This study also assessed client satisfaction at baseline with the performance of the M/N students in teaching women to self-inject. Four in five (80.5%) of the initial self-injectors did not realize that the provider was a student. Yet most were very (78.8%) or somewhat (9.7%) comfortable about learning to self-inject from a student. Most felt the M/N students were comfortable in explaining the method and its side effects (94.4%), and how to self-inject (99.4%). Close to 90% of acceptors were very satisfied with the information and counseling they received; 95.9% of acceptors would "strongly recommend" or "somewhat recommend" DMPA-SC self-injection to others.

At the 3-month follow-up, the findings were similar: 95.6% felt that the M/N students were very knowledgeable; 87.9% considered the explanations to be clear; and 93.5% found the M/N students to be "very respectful" toward them.

3.8. Feasibility of using M/N students to instruct clients in DMPA-SC self-injection {#s0090}
------------------------------------------------------------------------------------

"Feasibility" was not measured by a specific set of variables in a survey but rather by demonstration of the following:1.Is it possible for the D6 to train M/N students in family planning as part of their nursing curriculum?2.Once trained, are M/N students capable of instructing clients to self-inject DMPA-SC at the community level?3.Is the use of nursing students to deliver contraception in the community compatible with the existing system for delivering primary health care at the health zone level?

The experience of this research pilot provided strong evidence that all three are possible, further strengthening support for institutionalizing the family planning curriculum in the country\'s nursing schools.

4. Discussion {#s0095}
=============

This study demonstrated the feasibility of training M/N students to teach women at the community level to self-inject DMPA-SC in Kinshasa, DRC. It also showed that three in four clients interested in DMPA-SC were willing to try self-injection, at least in a setting where contraception was free and easily accessible.

Clients reported high levels of satisfaction both with DMPA-SC as a method and with self-injection as a procedure. Despite initial anxiety, by 3 months, they gained a high level of confidence in their ability to self-inject; few reported difficulties with the procedure or pain from it. Also, clients gave positive feedback regarding the performance of the M/N students: they were knowledgeable about DMPA-SC, they gave clear explanations, and they were respectful of the clients.

Our findings on the acceptability of DMPA-SC as a method are consistent with the results of the pilot introduction of the method in Burkina Faso, Niger, Senegal and Uganda from 2014 to 2016 [@bb0085], as well as our 2015 pilot in Kinshasa [@bb0080]. Our findings on high client satisfaction with self-injection concur with results from studies in Malawi and Uganda [@bb0090], [@bb0095]; clients who self-injected had higher continuation rates than those who received DMPA-SC from providers. In Niger, Senegal, Malawi and our studies in Kinshasa, the providers were community-based agents. By contrast, in the studies from Burkina Faso and Uganda, providers were clinic-based (e.g., trained nurses).

An important limitation of the research was the high loss to follow-up of DMPA-SC acceptors interviewed at baseline, resulting from (1) the team\'s delayed return for the 3-month follow-up (potentially affecting 15% of the baseline sample) and (2) difficulty in re-locating clients in communities where street names are not posted and houses often than have no numbers. Although clients could refuse the follow-up interview (when asked at baseline), some may have given false phone numbers to avoid further contact, especially if members of their household did not know they were using contraception.

This observational study was conducted under real-life conditions in highly impoverished neighborhoods of Kinshasa, with the aim of approximating the likely conditions in future expansion of this approach. In contrast to other self-injection studies where clients were recruited and taught to self-inject in a clinical setting [@bb0100], this study recruited clients through the mechanism of campaign days. Although the location for the campaign day was often adjacent to a health center, the project staff did not attempt to register the names of women in a client base, nor did they establish individual client records, as would be done in a clinic setting. For this reason, we do not report the proportion of acceptors enrolled in the study. Although less controlled, the "campaign approach" allowed women to obtain family planning counseling and the method of their choice (among the four available from the M/N, students) for free, with relatively little waiting time. By contrast, local health facilities charge for clinic inscription as well as the cost of the method, which often makes contraception unaffordable to this population. In addition, women often have to wait for 3--4 h or longer to receive family planning services in a clinic setting. However, the lack of detailed information on the clients served, including individual client records, hindered efforts to re-locate self-injection acceptors for the follow-up surveys. In short, the campaign approach increased access to modern contraception for women in these impoverished communities, yet it contributed to high loss to follow-up.

The implications of this high loss to follow-up over the course of the study are unclear. Data in [Table 1](#t0005){ref-type="table"} show that self-injectors followed through 6 and 12 months were slightly older and had more children. One hypothesis is that age might contribute to better adherence to a method, whereas having more children might provide additional motivation to use contraception. However, the magnitude of difference is small, suggesting a similar sociodemographic profile across the four rounds of data collection, despite attrition.

Although not reported herein, results from in-depth interviews with MOH officials and health zone officials indicated widespread acceptance for DMPA-SC self-injection as a method and for the use of M/N students to motivate and instruct women in its use in the community. The research team disseminated results from the studies of acceptors, M/N students and health authorities in Kinshasa in November 2017 as a first step to authorization for scale-up of this approach. In September 2018, the Minister of Health endorsed the scale-up of this approach, in addition to two other community-level strategies [@bb0110].

Efforts are already under way to institutionalize the use of M/N students for community-based distribution of contraceptives, including both DMPA-SC and Implanon NXT through the *6ème Direction* of the MOH, which is responsible for the network of nursing schools throughout the DRC.

Whereas the pilot research provides a clear model for operationalizing the use of nursing students to [administer]{.ul} contraception, the scale-up of [self-injection]{.ul} presents additional challenges, including the source of resupply and correct disposal of the device. DMPA-SC is still relatively scarce in Kinshasa (available in only 27.8% of pharmacies and health facilities) [@bb0015] and, even then, at prices that many women cannot afford. The major social marketing program provides DMPA-SC but uses its own personnel ("bees") to administer it [@bb0105]. Will local health centers allow women to purchase doses of DMPA-SC for home use without charging them the client inscription fee? A Kinshasa-wide community-based program, AcQual III, launched in mid-2018 will include a monthly campaign day in every health zone, where nursing students and community health workers (nonmedical profile) will offer contraceptives at a highly subsidized price; as such, it could be a source of supply for self-injectors. Yet even then, will project personnel require demonstration that shows a woman to be competent in self-injection? The researchers on this study will address this set of operational challenges to the scale-up of DMPA-SC self-injection in the next phase of programmatic research in Kinshasa.
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[^1]: The asterisks denote a statistically significant difference between the value obtained on this round and the baseline based on ANOVA and *χ*^2^ tests on the samples in baseline and three follow-up surveys: \*≤.05, \*\*≤.01, \*\*\*≤.001 (exact values available on request).

[^2]: All percentages are based on the *n* of 640, 504, 239 and 136, respectively, for baseline and 3-, 6- and 12-month follow-up except where indicated to the contrary.
